Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.50 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 7/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5662881 | 0.84 | TDP1 (0.54) | TDP1EPHX2NR1H2NR1H3HTR3E | |
| SCHEMBL13548761 | 0.81 | TLR7 (0.52) | TLR7PANK3HTR2CHTR3EHTR3B | |
| SCHEMBL5661835 | 0.78 | TLR7 (0.51) | TLR7PANK3HTR2CHTR3EHTR3B | |
| SCHEMBL13548746 | 0.77 | TLR7 (0.52) | TLR7PANK3HTR2CTYR | |
| SCHEMBL25190321 | 0.75 | TDP1 (0.51) | TDP1TLR7EPHX2HTR3EHTR3B | |
| SCHEMBL3536765 | 0.74 | TLR7 (0.57) | TLR7PANK3HTR2CEPHX2HTR3E | |
| SCHEMBL3536770 | 0.72 | TLR7 (0.57) | TLR7PANK3HTR2CGAARAB9A | |
| SCHEMBL3539520 | 0.70 | HTR2C (0.64) | TLR7PANK3HTR2CRAB9APRKD3 | |
| SCHEMBL14463776 | 0.70 | PANK3 (0.52) | TLR7PANK3HTR2C | |
| SCHEMBL13548679 | 0.69 | HTR2C (0.62) | TLR7PANK3HTR2CRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | TDP1 2818/4885TLR7 2132/4885PANK3 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.